Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C40H69NO12.C4H4O4 |
Molecular Weight | 1628.0229 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 32 / 32 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C\C(O)=O.[H][C@@]2(O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(OC)C(=O)[C@@H](C)C3=C(C)C[C@@](C)(O3)[C@]([H])(O[C@@H]4O[C@H](C)C[C@@H]([C@H]4O)N(C)C(C)C)[C@H]2C.[H][C@@]6(O[C@H]5C[C@@](C)(OC)[C@@H](O)[C@H](C)O5)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(OC)C(=O)[C@@H](C)C7=C(C)C[C@@](C)(O7)[C@]([H])(O[C@@H]8O[C@H](C)C[C@@H]([C@H]8O)N(C)C(C)C)[C@H]6C
InChI
InChIKey=KQRXEQGYUDDPNW-QXRSSOOUSA-N
InChI=1S/2C40H69NO12.C4H4O4/c2*1-16-28-40(12,47-15)33(43)23(6)31-21(4)18-39(11,53-31)35(52-37-30(42)27(17-22(5)48-37)41(13)20(2)3)24(7)32(25(8)36(45)50-28)51-29-19-38(10,46-14)34(44)26(9)49-29;5-3(6)1-2-4(7)8/h2*20,22-30,32,34-35,37,42,44H,16-19H2,1-15H3;1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*22-,23+,24+,25-,26+,27+,28-,29+,30-,32+,34+,35-,37+,38-,39-,40-;/m11./s1
Molecular Formula | C40H69NO12 |
Molecular Weight | 755.9754 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 16 / 16 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C4H4O4 |
Molecular Weight | 116.0722 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Mitemcinal (GM-611), an erythromycin-derived prokinetic agent, was developed by Chuga as an agonist of the motilin receptor. Mitemcinal acts by a novel mechanism whereby it stimulates and promotes peristalsis in the stomach and other segments of the gastrointestinal tract. This drug was studied as a potential treatment for gastric motility disorder, as well as reflux esophagitis, non-ulcer dyspepsia, and diabetic gastroparesis. Mitemcinal was involved in phase II clinical trials in Patients with diabetic gastroparesis. Although gastroparetic symptoms improved with both mitemcinal and placebo, the prominent placebo effect was not statistically exceeded by mitemcinal. That is why the development of this drug has stalled. In addition, mitemcinal has been studied in phase II for the treatment of irritable bowel syndrome, but this study was also discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: O43193 Gene ID: 2862.0 Gene Symbol: MLNR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/17785940 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00050882
12 weeks of treatment with oral tablets given twice a day of GM-611 (Mitemcinal) 5mg, 10mg
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:55:38 GMT 2023
by
admin
on
Fri Dec 15 15:55:38 GMT 2023
|
Record UNII |
XU63LQ260J
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
300000044523
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
DBSALT002825
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
MM-18
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
CHEMBL2110756
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
154802-96-7
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
C170187
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
XU63LQ260J
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
DTXSID101027165
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY | |||
|
11513721
Created by
admin on Fri Dec 15 15:55:38 GMT 2023 , Edited by admin on Fri Dec 15 15:55:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |